The Wall Street Journal reports that activist investor Elliott Investment Management has built a sizable stake in Bio-Rad Laboratories. The report, citing people familiar with the matter, says Elliott’s involvement is aimed at pressuring the life-science company to address concerns about its underperformance in the stock market. While the exact size of the stake is not specified in the available summary, it is described as “big,” indicating Elliott has taken a meaningful position. Elliott’s typical activist approach can include seeking changes to strategy, management focus, or corporate structure, although specific demands or next steps are not detailed in the provided account. Bio-Rad Laboratories, which operates in the life-sciences sector, has faced investor scrutiny tied to its share-price performance, according to the framing of the report. The Bloomberg entry reiterates the WSJ account, also indicating that Elliott has accumulated the stake to push for improvements related to the company’s stock performance.